PROPHYLACTIC PLATELET DOSE STRATEGY TO PREVENT BLEEDING IN THROMBOCYTOPENIA

预防血小板减少症出血的预防性血小板剂量策略

• 批准号: 7377042
• 负责人: RONALD G STRAUSS
• 金额: $ 0.05万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-03-01 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377042
• 关键词: PROPHYLACTIC; PLATELET; DOSE; STRATEGY; PREVENT

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. As platelet use continues to increase at a rate disproportionately higher than that of red blood cells, it is important to identify the most cost-effective strategies for providing platelet support. Identification and implementation of the most safe and cost effective strategies for providing platelet support is crucial for effective disease management without depleting platelet supplies. The primary objective of this study is to compare the three study arms of high, medium, and lower dose platelet therapy with respect to the percentage of patients experiencing at least one episode of Grade 2 or higher bleeding, as determined by the Platelet Dose Trial Bleeding Scale. Secondary objectives are to compare the three study arms with respect to platelet and hemostasis related outcomes (i.e., platelet utilization rates, frequency of transfusions, days of platelet support, number of days to first Grade 2+ bleeding, highest category of bleeding during time on the study, bleeding severity, etc.). A cost analysis will also be conducted.

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。由于血小板使用率继续以不成比例的高于红细胞使用率的速度增长，确定提供血小板支持的最具成本效益的策略是很重要的。确定和实施提供血小板支持的最安全和最具成本效益的战略，对于在不耗尽血小板供应的情况下有效地管理疾病至关重要。这项研究的主要目的是比较高、中、低剂量血小板治疗的三个研究分支的患者经历至少一次2级或更高程度出血的百分比，这是由血小板剂量试验出血分级确定的。次要目标是比较三个研究机构在血小板和止血相关结果(即，血小板利用率、输血频率、血小板支持天数、一级2级以上出血的天数、研究期间最高出血类别、出血严重程度等)方面的差异。还将进行成本分析。